Skip to main content

Table 3 Interaction of overall survival (OS) and disease-free survival (DFS) with histopathological variables

From: Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

   OS DFS
Variables Mean (95% CI) p value Mean (95% CI) p value
Sex Male 72.08 (62.61-81.55) 0.103 52.15 (42.12-62.18) 0.179
  Female 79.52 (71.55-87.50)   61.00 (49.16-72.85)  
Differentiation grade Well-moderate 77.62 (70.03-85.21) 0.408 56.25 (47.45-65.06) 0.649
  Poor 64.14 (48.53-79.75)   56.50 (38.35-74.64)  
Tumor stage I-II 80.75 (71.71-89.78) 0.167 70.31 (59.84-80.78) 0.002*
  III-IV 68.89 (58.72-79.05)   42.44 (32.30-52.58)  
MGMT methylation status Unmethylated 73.54 (65.17-81.90) 0.398 49.87 (34.54-65.20) 0.949
  Methylated 76.07 (67.82-84.32)   57.33 (47.55-67.12)  
Percentage MGMT expression Low 70.53 (60.02-81.05) 0.211 50.77 (39.35-62.20) 0.328
  High 77.04 (69.58-84.50)   58.62 (48.37-68.87)  
MGMT expression intensity Low 61.36 (45.99-76.72) 0.006* 47.76 (32.80-62.71) 0.171
  High 77.48 (70.75-84.21)   56.43 (47.39-65.47)  
Percentage CD133 expression Low 82.03 (72.97-91.10) 0.273 67.91 (56.68-79.14) 0.014*
  High 70.41 (61.33-79.50)   46.01 (35.06-56.97)  
CD133 expression intensity Low 77.90 (69.39-86.41) 0.642 59.76 (49.62-69.89) 0.517
  High 78.00 (67.92-88.08)   53.74 (39.44-68.05)  
High MGMT intensity CD133 ≥ 50% 73.06 (63.99-82.14) 0.032* 49.14 (36.25-62.04) 0.140
  CD133 < 50% 72.33 (61.82-82.84)   57.08 (44.64-69.51)  
Low MGMT intensity CD133 ≥ 50% 52.36 (30.53-74.19)   37.85 (18.87-56.83)  
  CD133 < 50% 69.50 (45.88-93.11)   64.50 (41.41-87.59)  
  1. Statistically significant variables (*p < 0.05). CI, confidence interval.